Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REPRONEX vs ANDEMBRY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing c AMP and promoting follicular development and estrogen synthesis.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Induction of ovulation in oligo-ovulatory or anovulatory women with functional hypothalamic-pituitary dysfunction (WHO Group II),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
Terminal elimination half-life: 24-30 hours (menotropins); clinically, it supports daily dosing during ovarian stimulation
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
REPRONEX is a glycoprotein hormone that is cleared primarily by the liver and kidneys. The metabolic pathways involve proteolytic degradation. The terminal half-life is approximately 4-12 hours after subcutaneous administration.
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Renal (approximately 80% as parent drug and metabolites); biliary/fecal (<5%)
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Approximately 10%; mainly albumin
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
0.2-0.5 L/kg; reflects distribution primarily in extracellular fluid
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
SC/IM: nearly 100%
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²).
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
Not recommended for use in pediatric patients (safety and efficacy not established).
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
No specific dose adjustment; use with caution due to potential for decreased renal function and increased risk of thromboembolic events.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
REPRONEX should only be used by physicians who are experienced in infertility treatment and capable of monitoring ovarian response. Ovarian hyperstimulation syndrome (OHSS) may occur, which can be severe and potentially fatal. Multiple births have been reported.
None.
Risk of ovarian hyperstimulation syndrome (OHSS), which can be severe,Risk of multiple gestation,Thromboembolic events,Ovarian torsion,Pulmonary complications (e.g., atelectasis, adult respiratory distress syndrome)
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,An organic intracranial lesion (e.g., pituitary tumor),Abnormal uterine bleeding of undetermined origin,Ovarian cyst or enlargement of unknown etiology,Pregnancy,Hypersensitivity to urofollitropin or any component
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
No specific food interactions documented. Maintain adequate hydration to reduce OHSS risk. Avoid excessive alcohol or caffeine as they may affect fertility.
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
REPRONEX (menotropins) is classified as FDA Pregnancy Category X. Studies have shown that menotropins can cause fetal harm when administered to a pregnant woman. There is no indication for use during pregnancy, as it is used for ovulation induction in infertility. If used inadvertently, there is a risk of multiple gestations and potential for congenital anomalies, but no specific teratogenic pattern has been established. Use is contraindicated in pregnant women.
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
It is unknown whether menotropins are excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio is available.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
REPRONEX is contraindicated in pregnancy and should not be used. No dosing adjustments are applicable as it is not indicated for use during pregnancy. Pharmacokinetic changes in pregnancy do not apply because the drug is not administered during pregnancy.
Do not use in pregnancy. No dose recommendations available; contraindicated.
REPRONEX (menotropins) is a gonadotropin preparation containing FSH and LH activity. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing and minimize ovarian hyperstimulation syndrome (OHSS) risk. Avoid use in primary ovarian failure. Administer intramuscularly; rotate injection sites. Concomitant h CG is required for final follicular maturation and ovulation trigger.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
Store REPRONEX in the refrigerator and protect from light.,Administer exactly as prescribed; do not change dose or schedule.,You may experience bloating, pelvic discomfort, or mood swings; report severe abdominal pain, nausea, or rapid weight gain (signs of OHSS) immediately.,Multiple pregnancy is possible; discuss risks with your doctor.,Use barrier contraception until instructed to attempt conception.,Do not drive or operate machinery if dizziness or visual disturbances occur.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REPRONEX vs ANDEMBRY, answered by our medical review team.
REPRONEX is a Gonadotropin that works by REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing c AMP and promoting follicular development and estrogen synthesis.. ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REPRONEX and ANDEMBRY depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REPRONEX is: Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.. The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REPRONEX and ANDEMBRY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REPRONEX is classified as Category C. REPRONEX (menotropins) is classified as FDA Pregnancy Category X. Studies have shown that menotropins can cause fetal harm when administered to a pregnant woman. There is no indica. ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.